Adalimumab Biosimilar - Anti-TNF alpha mAb - Research Grade
Source
DrugBank DB00051
Species
Human
Expression system
Mammalian
Molecular weight
144kDa
Purity
>85%
Buffer
PBS pH7.5
Delivery condition
Blue ice (+4°C)
Delivery lead time in business days
3-5 days if in stock; 3-5 weeks if production needed
Delivery Time
3-5 days if in stock; 3-5 weeks if production needed
Storage condition
4°C for short term; -20°C for long term
Brand
ProteoGenix
Aliases /Synonyms
Adalimumab,Adalimumab,TNF alpha,anti-TNF alpha
Reference
PX-TA1001
Note
For research use only. Not suitable for human use.
Isotype
IgG1
Clonality
Monoclonal Antibody
Description of Adalimumab Biosimilar - Anti-TNF alpha mAb - Research Grade
General information about Adalimumab
Adalimumab is a recombinant, human IgG1 monoclonal antibody directed against tumor necrosis factor-alpha (TNF-alpha), with immunomodulating activity. Upon administration, adalimumab binds to TNF-alpha, thereby preventing its binding to the p55 and p75 TNF cell surface receptors and inhibiting TNF-mediated immune responses. TNF-alpha, a pro-inflammatory cytokine, is upregulated in various autoimmune diseases.
We used this ab to reduce as a negative control for reducing caco-2 (IEC) cells exitation by exugenues TNFa. We measured IL8 secreation as a result of TNFa stimulation. 1ug/mL ofAdalimumab Biosimilar – Anti-TNF alpha mAb was enough to completly abolish IL8 secreation by TNFa stimulation in caco-2 cells.
Ofer Gover –
We used this ab to reduce as a negative control for reducing caco-2 (IEC) cells exitation by exugenues TNFa. We measured IL8 secreation as a result of TNFa stimulation. 1ug/mL ofAdalimumab Biosimilar – Anti-TNF alpha mAb was enough to completly abolish IL8 secreation by TNFa stimulation in caco-2 cells.